Combining liver treatments with cancer drugs before liver transplant
Part of Cancer, Digestive system clinical trials.
This study looks at whether combining different liver-directed treatments with newer cancer drugs can help people with liver cancer who are waiting for a liver transplant. It aims to see if these treatments are safe and helpful for a wider group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years old or older.
- You must have a diagnosis of hepatocellular carcinoma (a common type of liver cancer).
- Your cancer must be at an early or intermediate stage, not too advanced.
- Your cancer must not have spread outside the liver.
- You must not have a severe type of blood clot in the main liver vein.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at combining local treatments (like radiation or chemo delivered directly to the tumor) with newer drugs that fight cancer by blocking blood vessel growth and boosting the immune system. The goal is to see if this combination can help people whose liver cancer cannot be removed with surgery.
This study tests whether giving targeted therapy and immunotherapy at the same time or one after the other is better for shrinking liver tumors that can't be removed right now but might be removable after treatment.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.